The report "AI in Clinical Trials Market by Function (Patient Recruitment, Site Optimization, Data Management, Quality, Regulatory), Phase (I, II, III), Indication (Cancer, CNS, CVS), Tool, End-User (Pharma/Biotech, CRO, Hospitals) & Region - Global Forecast to 2030", is projected to reach USD 2.74 billion by 2030 from USD 1.35 billion in 2024, at a CAGR of 12.4 % from 2024 to 2030.
Browse 358 market data Tables and 58 Figures spread through 372 Pages and in-depth TOC on "AI in Clinical Trials Market by Function (Patient Recruitment, Site Optimization, Data Management, Quality, Regulatory), Phase (I, II, III), Indication (Cancer, CNS, CVS), Tool, End-User (Pharma/Biotech, CRO, Hospitals) & Region - Global Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/ai-in-clinical-trials-market-42687548.html
Several significant reasons drive the AI in clinical trials market. Primarily, AI accelerates data processing, allowing for significantly more efficient trial designs, patient enrolment, and real-time monitoring. AI can improve candidate selection while also decreasing trial time and cost. Pressure from upstream to downstream to make drug development more streamlined, combined with massive clinical data, has prompted the introduction of AI. Furthermore, regulatory support for AI applications in healthcare, such as trials, has promoted the use of sophisticated analytics to improve patient care outcomes and trial efficiency.
End-to-end solutions segment accounted for the largest share of the AI in clinical trials market in 2023, by offering.
End-to-end solutions segment accounted for the largest market share in the AI in clinical trials market in 2023, by offering, as end-to-end solutions offer complete support throughout the trial process, including recruitment and patient monitoring, and also data analysis and regulatory submission. These are the pharmaceutical and biotech companies that usually does the main part of the process, for instance, streamlining operations, reducing costs, and improving efficiencies by integrating several trial stages under a single supplier, thus, making a great contribution to the sector in a highly competitive landscape.
The phase III segment to account for largest share of AI in clinical trials market for the year 2023, by phase
In AI in clinical trials market, Phase III segment will have largest share due to large-scale drug efficacy and safety testing among varied patient populations for regulatory approval and commercialization. Tools used in Phase III with the support of AI mobilize huge data collection, patient monitoring, and predictive analytics. The high price, complexity, and regulatory importance of Phase III trials encourage investment in AI for streamlining and saving time with guaranteed successful outcomes of the trial.
North America accounted for the largest share of the AI in clinical trials market in 2023.
North America held the most significant market share in the AI in clinical trials market in 2023. This region has a developed infrastructure concerning healthcare, the region has significant investments in R&D compared to their Asian counterparts, and it is home to leading pharmaceutical and biotechnology companies. Moreover, in North America, the regulatory environment and agencies like FDA support the integration of AI in clinical trials for better clinical trial processes. Well, highly adopted digital technologies and robust availability of data have pushed forward the fast implementation of AI solutions across, which has allowed for even more efficient trial designs, patient recruitments, and real-time analysis of data.
Prominent players in the AI in clinical trials market include are IQVIA Inc. (US), Saama. (US), Dassault Systèmes (Medidata) (France), Phesi (US), PathAI, Inc. (US), Unlearn.ai, Inc. (US), Deep6.ai (US), Microsoft (US), IBM (US), NVIDIA Corporation (US), Insilico Medicine (US), ConcertAI. (US), AiCure. (US), Median Technologies. (France), Lantern Pharma Inc. (US), Citeline, a Norstella Company (US), Tempus AI, Inc. (US), TriNetX, LLC (US), ReviveMed Inc. (US), Euretos. (US), VeriSIM Life. (US), Triomics (US), Ardigen (Poland), QuantHealth Ltd. US), and DEEP GENOMICS. (Canada).
Comments (0)